Complementary platforms that act alone or in combination with other treatments to treat cancer and chronic diseases.

Nibrozetone (RRx-001) Program

Study Indication Preclinical Phase 1 Phase 2 Phase 3
3L+ SCLC “REPLATINUM” Phase 3 in US & China for sensitization/resensitization of tumors to 1st line platinum-based chemo + [read more] Small Cell Lung Cancer (SCLC)
1L Radiation Protection in Head & Neck Cancer + [read more] Oral Mucositis, Chemo-radiation induced in Head & Neck Cancer (HNC)
PD-1 Immune Checkpoint Resistance Abrogation + [read more] Solid tumors, Head & Neck Cancer (HNC)
Neurodegenerative diseases + [read more] Parkinson’s, ALS/MND and others
Endometriosis reduction + [read more] Endometriosis
3/4L RRx-001 + Irinotecan vs Regorafenib in Subjects with Metastatic Colorectal Cancer + [read more] Metastatic Colorectal Cancer (mCRC)
Active programs

ADAPT-001 TGF-beta Trap Program

Study Indication Preclinical Phase 1 Phase 2 Phase 3
Intratumoral administration + [read more] Rare refractory solid tumors
Hepatic artery infusion (HAI) administration + [read more] Liver metastases in Metastatic Colorectal Cancer (mCRC)
AdAPT Nanoparticle Encapsulation Optimization of AdAPT Platform treatments for improved delivery and performance
Active programs

Partnership Opportunities: We welcome regional and global partnerships with like-minded companies, institutions, and investors that support our first-in-class therapies and treatment programs in oncology, radioprotection, and neurodegenerative and gynecological diseases.